AMAG Pharmaceuticals Given New $25.00 Price Target at Ladenburg Thalmann (AMAG)
Equities researchers at Ladenburg Thalmann dropped their target price on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from $27.00 to $25.00 in a research report issued on Monday, American Banking News reports. The firm currently has a “buy” rating on the stock. Ladenburg Thalmann’s price objective would indicate a potential upside of 16.42% from the stock’s previous close.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 0.81% on Monday, hitting $21.474. The stock had a trading volume of 209,189 shares. AMAG Pharmaceuticals has a 52-week low of $13.85 and a 52-week high of $27.00. The stock has a 50-day moving average of $24.11 and a 200-day moving average of $22.79. The company’s market cap is $465.7 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Thursday, August 1st. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.17) by $0.08. The company had revenue of $19.60 million for the quarter, compared to the consensus estimate of $18.51 million. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was down 36.8% on a year-over-year basis. Analysts expect that AMAG Pharmaceuticals will post $-0.51 EPS for the current fiscal year.
A number of other firms have also recently commented on AMAG. Analysts at Leerink Swann raised their price target on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from $23.00 to $25.00 in a research note to investors on Friday, August 2nd. Analysts at Jefferies Group raised their price target on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from $14.00 to $16.00 in a research note to investors on Friday, August 2nd. They now have an “underperform” rating on the stock.
AMAG Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (NASDAQ:AMAG).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.